Bioactive interbody devices in lumbar fusions prove cost-effective: study

Spinal Tech

NuVasive's porous interbody implant and synthetic bone graft substitutes are a cost-effective option for later lumbar interbody fusions, a study in the Journal of Neurosurgery found. 

Three things to know:

1. The retrospective study, published June 3, consisted of 90 patients who had lateral lumbar interbody fusions with NuVasive's Attrax Putty and its Modulus XLIF implant. The mean age was 69 years old, and most patients were female.

2. The use of synthetic biologics and interbody implants with advanced surface technologies led to a high rate of effective fusion after 12 months in 97.8 percent of patients, while using a smaller volume of biologic material.

3. The study concluded: "The use of bioactive titanium interbody devices with a large surface footprint appears to result in a very high rate of effective fusion, despite the use of a small volume of low-cost biological material. This potential change in the osteobiologics required to achieve high fusion rates may have a substantially beneficial impact on the economic burden inherent to spinal fusion."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers